Psychiatry

 
Suicide Prevention in Primary Care: A Family Physician on Screening, Risk, and Follow-Up
April 23, 2025

Suicide prevention falls squarely in the purview of primary care practitioners, says family physician Teresa Lovins, MD. She reviews an intervention with remarkable results.

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose
April 21, 2025

Your daily dose of the clinical news you may have missed.

Bringing Behavioral Health Into Primary Care: A Collaborative Care Roadmap
April 17, 2025

ACP 2025: Matthew Press, MD, shares actionable steps for primary care physicians to adopt a collaborative care model, including how to start small and partner with other practices.

Matthew Press, MD: How Penn Medicine’s CoCM Model Helps PCPs Treat Mental Health—and Avoid Burnout
April 15, 2025

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

Collaborative Care for Mental Health: A Scalable, Team-Based Model for Primary Care
April 11, 2025

ACP 2025: Discover how the collaborative care model supports mental health in primary care through team-based care, symptom tracking, and psychiatric consultation—boosting outcomes and reducing burden on clinicians.

Methylone (TSND-201) for PTSD Shows Rapid, Sustained Symptom Improvement in Phase 2 IMPACT-1 Trial
April 01, 2025

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

Pediatric Fentanyl Poisonings Spiral Up 1,200% Over 8 Years, Study Finds
March 28, 2025

In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.

Nearly Half of Adults Diagnosed with MDD May Have Treatment Resistant Depression, Many Feel Hopeless
March 25, 2025

More than one-third of study participants with TRD had failed to get relief from 4 or more antidepressants, calling treatment experiences a "trial and error" process.

FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025
March 04, 2025

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.